PathPlus™ validated antibodies from LSBio
Is cancer diagnostics in crisis?
A crisis in non-communicable diseases is brewing as a result of the pandemic, the WHO warns. In particular, neglected cancer screening will lead to many avoidable deaths in the coming years due to delayed diagnoses. (WHO press release on World Cancer Day) These fears make cancer research and the development of new markers for the early detection of different types of cancer all the more important.
The antibodies in the LSBio PathPlus™ Cancer series include well-established biomarkers for cancer, as well as markers for clarifying questions about etiology, subclassification and pathogenesis.
PathPlus Antikörper iLSBio PathPlus™ antibodies represent the highest quality reagents available for research pathology applications. This series of reagents was selected from among thousands of antibodies that were tested in immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) tissues to be the best performers. Each antibody has been tested on 25 human tissues, including specialized tissues such as cancers or brain regions, compared to up to 20 different antibodies to that target, and ranked by performance. The antibodies that showed the highest specificity and least nonspecific staining on formalin-fixed paraffin-embedded tissues are now available for your research, designated by the PathPlus™ brand.
Whether investigating cancer biomarkers, neurodegenerative diseases, apoptotic pathways or lymphocyte subsets in immune disorders, the LSBio PathPlus™ antibodies are guaranteed to work in IHC for research pathology applications.